Central Nervous System Agents in Medicinal Chemistry
Title:Acknowledgements to Reviewers
Volume: 17 Issue: 3
Author(s):
Affiliation:
Export Options
About this article
Cite this article as:
, Acknowledgements to Reviewers, Central Nervous System Agents in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/187152491703171025150950
DOI https://dx.doi.org/10.2174/187152491703171025150950 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
11
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design The Response of the Aged Brain to Stroke: Too Much, Too Soon?
Current Neurovascular Research Mitochondrial Dysfunction in Depression
Current Neuropharmacology Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews Stroke Induced Immunodepression Syndrome: From Bench to Bedside
Current Molecular Medicine Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Role of Sigma Receptors in Methamphetamine-Induced Neurotoxicity
Current Neuropharmacology Chlorogenic Acid and Mental Diseases: From Chemistry to Medicine
Current Neuropharmacology From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments
Current Pharmaceutical Design Proposition of Potential GSK-3β Inhibitors for the Treatment of Alzheimer’s Disease: A Molecular Modeling Study
Current Computer-Aided Drug Design Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD)
Current Respiratory Medicine Reviews Preliminary Studies on Optimization of Anti-Parkinson Drug Loaded Lipid Nanoparticles Enriched Hydrogel Formulations for Management of Parkinson’s Disease
Current Nanomedicine Protein Chimera-based Ca2+ Rewiring as a Treatment Modality for Neurodegeneration
Current Psychopharmacology Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Current Drug Abuse Reviews Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies Antioxidant and Anticholinesterase Activities of Some Dialkylamino Substituted 3-Hydroxyflavone Derivatives
Medicinal Chemistry The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review
Current Neuropharmacology Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design